Compare · EAR vs NTRA
EAR vs NTRA
Side-by-side comparison of Eargo Inc. (EAR) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EAR and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA carries a market cap of $41.68B.
- NTRA has hit the wire 33 times in the past 4 weeks while EAR has been quiet.
- NTRA has more recent analyst coverage (25 ratings vs 3 for EAR).
- Company
- Eargo Inc.
- Natera Inc.
- Price
- -
- -
- Market cap
- -
- $41.68B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2015
- News (4w)
- 0
- 33
- Recent ratings
- 3
- 25
Eargo Inc.
Eargo, Inc., a medical device company, develops and sells hearing aids to assist people with hearing loss in the United States. It sells its products through online stores. The company was formerly known as Aria Innovations, Inc. and changed its name to Eargo, Inc. in November 2014. Eargo, Inc. was founded in 2010 and is headquartered in San Jose, California.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest EAR
- SEC Form 15-12G filed by Eargo Inc.
- SEC Form S-8 POS filed by Eargo Inc.
- SEC Form S-8 POS filed by Eargo Inc.
- SEC Form S-8 POS filed by Eargo Inc.
- Brownie William returned 296 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Narula Onkarr
- Wu David James returned 25,463 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Sabet-Peyman Afshin Justin
- SEC Form 4 filed by Bayne Katie J
- SEC Form 4 filed by Spence Donald J
Latest NTRA
- HLTH 2026 Names Natera Best-in-Class Winner in Cancer, Screening & Early Detection
- Amendment: SEC Form SCHEDULE 13G/A filed by Natera Inc.
- CO-FOUNDER Sheena Jonathan sold $478,945 worth of shares (1,500 units at $319.30) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form S-3ASR filed by Natera Inc.
- SEC Form S-8 filed by Natera Inc.
- CO-FOUNDER Sheena Jonathan sold $975,623 worth of shares (3,086 units at $316.14) as part of a pre-agreed trading plan and sold $19,781 worth of Common Stock (64 units at $309.08) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 214,462 units (SEC Form 4)
- Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer
- Amendment: SEC Form SCHEDULE 13G/A filed by Natera Inc.
- SEC Form 10-Q filed by Natera Inc.
- Natera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits